ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.